HC Wainwright & Co. Reiterates Buy on Savara, Maintains $10 Price Target
Savara Analyst Ratings
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Savara Analyst Ratings
JMP Securities Maintains Market Outperform on Savara, Lowers Price Target to $9
Buy Rating Affirmed for Savara on Molbreevi's Commercial Promise and Solid Financial Footing
Guggenheim Maintains Buy on Savara, Raises Price Target to $10
Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating
HC Wainwright & Co. Maintains Buy on Savara, Raises Price Target to $10
Savara Analyst Ratings
Oppenheimer Maintains Outperform on Savara, Raises Price Target to $15
Oppenheimer: Maintaining the Savara (SVRA.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $9.50 to $11.00.
Savara Analyst Ratings
Oppenheimer Maintains Outperform on Savara, Raises Price Target to $11
Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)
Savara Analyst Ratings
Evercore ISI Group Maintains Outperform on Savara, Lowers Price Target to $7
Evercore ISI Group: Maintaining the Savara (SVRA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $10.00 to $7.00.
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)
No Data